1. Home
  2. NDLS vs XBIT Comparison

NDLS vs XBIT Comparison

Compare NDLS & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Noodles & Company

NDLS

Noodles & Company

HOLD

Current Price

$16.40

Market Cap

68.7M

ML Signal

HOLD

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.27

Market Cap

69.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NDLS
XBIT
Founded
1995
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Pharmaceuticals and Biotechnology
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.7M
69.8M
IPO Year
2013
2015

Fundamental Metrics

Financial Performance
Metric
NDLS
XBIT
Price
$16.40
$2.27
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
64.7K
32.6K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$495,089,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.37
N/A
52 Week Low
$0.47
$2.09
52 Week High
$19.00
$3.61

Technical Indicators

Market Signals
Indicator
NDLS
XBIT
Relative Strength Index (RSI) 53.90 45.21
Support Level $10.71 $2.16
Resistance Level $16.10 $2.32
Average True Range (ATR) 1.40 0.04
MACD 0.06 0.01
Stochastic Oscillator 56.69 42.11

Price Performance

Historical Comparison
NDLS
XBIT

About NDLS Noodles & Company

Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services. It is focused on offering customers flavorful, cooked-to-order dishes in a warm and welcoming environment at an attractive value. It has approximately 340 company-owned restaurants and 83 franchise restaurants in 31 states.

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Share on Social Networks: